Why the study?
Does combination therapy with a calcium channel blocker and an ACE inhibitor improve blood pressure control and adherence in patients with arterial hypertension?
Does combination therapy with a calcium channel blocker and an ACE inhibitor improve blood pressure control and adherence in patients with arterial hypertension?
A fixed-dose combination of lercanidipine and enalapril offers synergistic blood pressure reduction, target organ protection, and improved patient adherence in the management of arterial hypertension.
Answers are grounded in this paper and cite their sources.
May support adherence in hypertension; leaves open whether benefits exceed other CCB-ACEI regimens in randomized trials.
The paper emphases the need for dual antihypertensive therapy and describes its benefits, such as synergetic hypotensive action and other beneficial effects. One of the pathogenetically justified variants of combination therapy – a third-generation dihydropyridine calcium channel antagonist and an angiotensin-converting enzyme inhibitor – is discussed in more detail.
No takes yet. Share an insight, caveat, or question.
Е. О. Таратухин (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: